Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Down 50.0% in June

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the recipient of a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 200 shares, a decline of 50.0% from the June 15th total of 400 shares. Based on an average daily trading volume, of 2,300 shares, the short-interest ratio is currently 0.1 days.

Clinuvel Pharmaceuticals Stock Up 0.5 %

Clinuvel Pharmaceuticals stock traded up $0.05 during mid-day trading on Friday, hitting $10.35. The company’s stock had a trading volume of 254 shares, compared to its average volume of 3,218. Clinuvel Pharmaceuticals has a 52-week low of $8.54 and a 52-week high of $13.55. The firm’s 50 day moving average is $10.05 and its 200 day moving average is $9.96.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).